Gene Polymorphisms of CD207 (Langerin) Are Associated With End-Stage Renal Disease.
The CD207 molecule, also known as langerin, is known to be the first immunologic barrier expressed on Langerhans cells, which are the immature dendritic cells of the epidermis and mucosa. Inflammation could be a causal factor in the progression of chronic kidney disease. To date, convincing experimental and clinical evidence indicates that langerin plays a role in antigen uptake and processing, which is the primary function of Langerhans cells. In this study, we hypothesized that polymorphisms of the CD207 (Langerin) gene may be associated with end-stage renal disease (ESRD). To evaluate whether an association exists between CD207 and ESRD susceptibility, we assessed the relation between 10 exonic single-nucleotide polymorphisms (SNPs) in the CD207 gene and ESRD in 90 kidney transplant patients and 545 control subjects. Compared with the control participants, the frequencies of the CD207 rs13421115*T and rs17718987*C alleles were significantly higher in the patients with ESRD. Genotyping analysis demonstrated that 2 SNPs (rs13421115 and rs17718987) included in the study were significantly associated with ESRD in the codominant1 (rs13421115; Fisher exact P = .027), dominant (rs13421115; Fisher exact P = .004; and rs17718987; Fisher exact P = .004), and log-additive (rs13421115; Fisher exact P = .004; and rs17718987; Fisher exact P = .004) models after adjusting for age and sex. We suggest that CD207 gene polymorphisms rs13421115 and rs17718987 increase the risk of development of ESRD.